Targeting and disabling a certain protein essential to transporting glucose properly through cells (Glucose Transporter 1, or ...

A study funded in part by the National Institutes of Health (NIH) has revealed important insights into the genetics of deposits in the eye, known as reticular pseudodrusen (RPD), that are linked to ...

A single-dose gene replacement therapy is found to improve movement ability in children over 2 years of age and teenagers with spinal muscular atrophy, according to research published in Nature ...

In a new study, researchers examined the Renal Activity Index for Lupus (RAIL) diagnostic tool to assess its success for ...

The Trump administration has whiffed its deadline to ban lab-made pandemic viruses by more than eight weeks, worrying biosafety hawks and undercutting assurances from the National Institutes of Health ...

BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Drinking as little as one can of diet soda a day may increase the risk of non-alcoholic fatty liver disease by 60%, while drinking a sugary beverage could raise the risk by 50%, a new unpublished ...

BETHESDA, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Stanley is an associate professor and Richard and Rhoda Goldman distinguished chair in the biological sciences as well as faculty director for the Alliance for Global Health and Science at the ...

Biosafety hawks were initially optimistic that the incoming second Trump administration would at last place binding constraints on so-called "dangerous gain-of-function" research, in which pathogens ...

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled 21 ...